Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit

Robert J. Walsh, Rebecca Hui Shan Ong, Seng Wee Cheo, Peter Q.j. Low, Aishwarya Jayagopal, Matilda Lee, Natalie Y.l. Ngoi, Samuel G.w. Ow, Andrea L.a. Wong, Siew Eng Lim, Yi Wan Lim, Valerie Heong, Raghav Sundar, Ross A. Soo, Cheng Ean Chee, Wei Peng Yong, Boon Cher Goh, Soo Chin Lee, David S.p. Tan, Joline S.j. LimFrontiers in Oncology 2024 · DOI

Abstract

Broad-panel next-generation sequencing (NGS) in metastatic breast cancer (MBC) is feasible in an Asian clinical setting, allowing for therapeutic matching. This approach was associated with significant improvements in both progression-free survival (PFS) and overall survival (OS).

Introduction

While precision oncology has transformed the management of cancers like lung cancer and melanoma, its application in metastatic breast cancer (MBC) has traditionally been limited to hormone receptor (ER/PR) status and HER2 expression. However, many MBC tumors harbor actionable genomic alterations that fall outside these standard categories. Furthermore, most large-scale genomic studies have focused on Western populations. This study investigates whether a routine molecular profiling program in an Asian tertiary oncology unit can successfully identify these mutations and if matching patients to targeted therapies leads to improved clinical outcomes in a real-world, early-phase trial setting.

Methods and Data

The researchers analyzed the Integrated Molecular Analysis of Cancer (IMAC) study cohort at the National University Cancer Institute, Singapore, involving 215 patients with MBC enrolled between 2014 and 2022. The study tracked the evolution of sequencing technology, transitioning from a 50-gene hotspot panel to the broader FoundationOne CDx platform (300+ genes). Genomic results were reviewed by a Molecular Tumor Board (MTB), and patients were prioritized for matched therapeutic trials. The analysis compared "matched" treatment events (targeting a detected mutation) against "unmatched" events (standard chemotherapy or non-genomic trials).

Genomic Landscape of Metastatic Breast Cancer

The study revealed a high frequency of actionable mutations. The PI3K/AKT/PTEN pathway was altered in 62% of the cohort, with PIK3CA mutations alone appearing in 43% of tumors. TP53 (47%) was the most frequently mutated gene overall, with a higher prevalence in ER-negative tumors (65% vs 38%). Additionally, 13% of patients exhibited a high Tumor Mutational Burden (TMB ≥ 10 mt/Mb), identifying them as potential candidates for immunotherapy.

Oncoprint showing the most frequent genomic alterations in the MBC cohort.

Clinical Outcomes and Survival Analysis

The most significant finding was the survival advantage associated with matched therapy. Patients receiving matched treatments experienced a median progression-free survival (PFS) of 21.0 weeks, compared to 12.1 weeks for those receiving unmatched treatments (HR 0.63; p = 0.034). Even more striking was the difference in overall survival (OS): patients who received matched therapy at any point lived a median of 30.1 months, versus 11.8 months for the unmatched group (HR 0.45; p = 0.013).

Comparison of PFS and OS between matched and unmatched treatment groups.

The utility of NGS profiling increased over time as the availability of targeted drugs and clinical trials expanded. The rate of successful matching rose from 11% in the initial phase to 35% in the most recent group, suggesting that the clinical value of broad-panel sequencing grows alongside the therapeutic landscape.

Discussion and Limitations

Despite the promising results, the study has limitations, including its retrospective design and the evolution of sequencing panels over time, which may have led to an underestimation of benefits for early participants. Small subgroup sizes for certain pathways, such as DNA Damage Response (DDR), also limited definitive analysis. Future work should focus on larger, multi-center prospective trials in Asian populations to refine the use of broad-panel NGS and explore rare mutations that currently lack dedicated trial options.

Summary updated

Abstract

Broad-panel NGS in MBC is feasible, allowing therapeutic matching, which was associated with improvements in PFS and OS.
BibTeX
@inproceedings{walsh2024molecular,
  author = {Robert J. Walsh and Rebecca Hui Shan Ong and Seng Wee Cheo and Peter Q.J. Low and Aishwarya Jayagopal and Matilda Lee and Natalie Y.L. Ngoi and Samuel G.W. Ow and Andrea L.A. Wong and Siew Eng Lim and Yi Wan Lim and Valerie Heong and Raghav Sundar and Ross A. Soo and Cheng Ean Chee and Wei Peng Yong and Boon Cher Goh and Soo Chin Lee and David S.P. Tan and Joline S.J. Lim},
  title = {{Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit}},
  booktitle = {Frontiers in Oncology},
  year = {2024},
  doi = {10.3389/fonc.2024.1342346},
}
Figure